secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001437749-25-037547
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics starts Phase 2 trial of PIPE-791 for IPF; 324 subjects, completion June 2028
--------------------------------------------------------------------------------

- Submitted Phase 2 trial details for PIPE-791 to ClinicalTrials.gov; expects ~324 IPF patients enrolled globally.
- Trial is 26-week, randomized, dose-ranging, double-blind, placebo-controlled, once-daily dosing.
- Primary efficacy endpoint: change from baseline in forced vital capacity (FVC) at week 26.
- Trial design informed by regulatory feedback and completed Phase 1 data; completion expected June 2028.
- No financial guidance or capital structure changes included in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925037547/0001437749-25-037547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925037547/ctnm20251204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer